Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 10 of 67

1.

Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation.

Dilokthornsakul P, Patidar M, Campbell JD.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2017; 20(10):1329-1335.

PubMed [journal]
PMID:
29241892
2.

Value of Public Health Funding in Preventing Hospital Bloodstream Infections in the United States.

Whittington MD, Bradley CJ, Atherly AJ, Campbell JD, Lindrooth RC.

American journal of public health. 2017; 107(11):1764-1769.

PubMed [journal]
PMID:
28933936
3.

Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?

Kim CH, Dilokthornsakul P, Campbell JD, van Boven JFM.

The journal of allergy and clinical immunology. In practice. 2017;

PubMed [journal]
PMID:
28967548
4.

Recommendations for Methicillin-Resistant Staphylococcus aureus Prevention in Adult ICUs: A Cost-Effectiveness Analysis.

Whittington MD, Atherly AJ, Curtis DJ, Lindrooth RC, Bradley CJ, Campbell JD.

Critical care medicine. 2017; 45(8):1304-1310.

PubMed [journal]
PMID:
28471887
5.

Screening test recommendations for methicillin-resistant Staphylococcus aureus surveillance practices: A cost-minimization analysis.

Whittington MD, Curtis DJ, Atherly AJ, Bradley CJ, Lindrooth RC, Campbell JD.

American journal of infection control. 2017; 45(7):704-708.

PubMed [journal]
PMID:
28126259
6.

Impact of Nonmedical Vaccine Exemption Policies on the Health and Economic Burden of Measles.

Whittington MD, Kempe A, Dempsey A, Herlihy R, Campbell JD.

Academic pediatrics. 2017; 17(5):571-576.

PubMed [journal]
PMID:
28286295
7.

Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.

Whittington MD, McQueen RB, Ollendorf DA, Tice JA, Chapman RH, Pearson SD, Campbell JD.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2017; 118(2):220-225.

PubMed [journal]
PMID:
27923549
8.

Measuring the cost of poor asthma control and exacerbations.

Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ.

The Journal of asthma : official journal of the Association for the Care of Asthma. 2017; 54(1):24-31.

PubMed [journal]
PMID:
27286240
9.

Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?

Dilokthornsakul P, Chaiyakunapruk N, Campbell JD.

The Journal of asthma : official journal of the Association for the Care of Asthma. 2017; 54(1):17-23.

PubMed [journal]
PMID:
27284904
10.

Measurement of utility in asthma: evidence indicating that generic instruments may miss clinically important changes.

Sullivan PW, Ghushchyan VH, Campbell JD, Globe G, Bender B, Magid DJ.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2016; 25(12):3017-3026.

PubMed [journal]
PMID:
27387417
Support Center